RxDoctor Payments Data

Hassan Honainy, MD

Nephrology · Low Moor, VANPI 1932104023

Payments from drug & device makers

$3,237in general payments, 2019–2025

Across 176 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$574
  • Travere Therapeutics, Inc.$493
  • AstraZeneca$423
  • Otsuka America Pharmaceutical, Inc.$292
  • Bayer$236
  • Amgen$218
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,05994%
  • Education$1796%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,237 in reported general payments places this provider in the 70th percentile of 298 nephrology providers in Virginia.

See all nephrology providers in Virginia

Medicare billing

Part B allowed, 2024
$221,881
Medicare patients
898
Services billed
2,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide173$182,468
FarxigaDapagliflozin Propanediol73$81,365
MounjaroTirzepatide57$67,130
EliquisApixaban37$39,008
RayaldeeCalcifediol26$32,018
JardianceEmpagliflozin21$30,142
Sevelamer Carbonate50$23,148
TradjentaLinagliptin15$19,021
ClinolipidFat Emulsion/Olive/Soy/Phospho32$14,171
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,259
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,802
Calcium Acetate49$3,076
ProsolParenteral Amino Acid 20% No.114$2,854
Midodrine Hcl25$2,166
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$574$182,468173 claims
AstraZenecaFarxiga, Breztri Aerosphere$423$91,16788 claims
Lilly USA, LLCMounjaro, Humalog$33$68,99669 claims
Boehringer IngelheimJardiance, Tradjenta$53$49,16436 claims
OPKO Pharmaceuticals, LLCRayaldee$67$32,01826 claims
GSKTrelegy Ellipta$49$10,25916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 298 nephrology providers in Virginia.

Other nephrology in Low Moor

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →